Phreesia, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phreesia, Inc. on August 11, 2023. The filing primarily addresses the unregistered sale of equity securities issued as partial consideration for two recent acquisitions: MediFind (closed June 30, 2023) and Access eForms (closed August 11, 2023). The report also includes a legal opinion regarding the legality of these shares for future resale.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on transaction details and share issuance.
Material Changes and Transactions
- MediFind Acquisition: Closed on June 30, 2023. Total consideration was approximately $9,000,000. The Company issued 150,786 shares of Common Stock as partial consideration.
- Access eForms Acquisition: Closed on August 11, 2023. Total consideration was approximately $43,000,000. The Company issued 1,096,436 shares of Common Stock as partial consideration.
- Total Equity Issuance: A combined total of 1,247,222 shares of Common Stock were issued for these two transactions.
- Valuation Basis: Share counts were calculated based on volume-weighted average prices (60-day for MediFind; 30-day for Access eForms).
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The primary contingency noted is that cash portions of the consideration for both acquisitions are subject to customary working capital and purchase price adjustments. The shares were issued in reliance on the Section 4(a)(2) exemption from registration under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final purchase price adjustments for both the MediFind and Access eForms acquisitions.
- Confirm the exact number of shares issued once any final adjustments are calculated.
- Review the Resale Prospectus Supplement to understand the timeline for when the issued shares may be sold by the selling stockholders.
- Assess the impact of the $52,000,000 combined acquisition cost on the Company's cash position and future liquidity.